Asymmetric multispecific antibodies
The present invention relates to multispecific antibodies, for example bispecific antibodies, and methods for the isolation or purification of the same. The antibodies of the invention comprise first and second heavy chain-light chain pairings wherein each pairing comprises a distinct selective recognition site including one or more amino acid residues contributed from the heavy chain and the light chain of the pairing. The first and second selective recognition sites differ by at least one amino acid residue and can be differentially bound by first and second selective recognition agents according to the methods of the invention. Such methods facilitate the production of antibody preparations enriched for multispecific antibodies having the correct functional heavy chain-light chain pairings.
1. A bispecific IgG antibody comprising
(i) a first pairing comprising a first CH1 domain and a first CL domain, wherein the first pairing comprises a first antigen binding site; and
(ii) a second pairing comprising a second CH1 domain and a second CL domain, wherein the second pairing comprises a second antigen binding site, wherein:
(a) the first CH1 domain and the second CH1 domain are of different human immunoglobulin subtypes selected from the group consisting of IgG1, IgG2, IgG3 and IgG4, or the first CH1 domain and the second CH1 domain—are of different human immunoglobulin allotypes selected from the group consisting of IGGH1.1 (SEQ ID NO: 1), IGGH1.3 (SEQ ID NO: 2), IGGH2 (SEQ ID NO: 3), IGGH2.2 (SEQ ID NO: 4), IGGH2.4 (SEQ ID NO: 5), IGGH4 (SEQ ID NO: 6), IGGH3 (SEQ ID NO: 7), IGG3.17 (SEQ ID NO: 8), and IGGH3.18 (SEQ ID NO: 9),
(b) the first CL domain is a human lambda light chain and the second CL domain is a human kappa light chain,
(c) the human lambda light chain is of a human immunoglobulin allotypes selected from the group consisting of IGLC1*01 (SEQ ID NO: 10), IGLC2*01 (SEQ ID NO: 11), IGLC3*01 (SEQ ID NO: 12), IGLC7*01 (SEQ ID NO: 13), and IGLC6*01 (SEQ ID NO: 14),
(d) the first CH1 domain and the second CH1 domain differ at one or more positions selected from the group consisting of positions 131, 133, 137, 138, 178, 192, and 193, wherein:
(i) at position 131: C in the first CH1 domain; S in the second CH1 domain; and/or
(ii) at position 133: R in the first CH1 domain; K in the second CH1 domain; and/or
(iii) at position 137: E in the first CH1 domain; G in the second CH1 domain; and/or
(iv) at position 138: S in the first CH1 domain; G in the second CH1 domain; and/or
(v) at position 178: S in the first CH1 domain; Y in the second CH1 domain; and/or
(vi) at position 192: N in the first CH1 domain; S in the second CH1 domain; and/or
(vii) at position 193: F in the first CH1 domain; L in the second CH1 domain and wherein the position is based on EU numbering.
2. The bispecific IgG antibody of claim 1 wherein the first CH1 domain and the second CH1 domain are of different human immunoglobulin subtypes.
3. The bispecific IgG antibody of claim 1 wherein the first CH1 domain and the second CH1 domain are of different human immunoglobulin allotypes.
4. The bispecific IgG antibody of claim 1 wherein the antibody is monovalent.
5. An isolated VHH antibody comprising the amino acid sequence of SEQ ID NO: 15 that recognizes a human CH1 domain comprising at least one amino acid substitution selected from the group consisting of R133K, E137G, S138G, N192S, F193L, and S178Y, and wherein the position of the substitution is based on EU numbering.
6. An isolated VHH antibody comprising (i) an amino acid sequence selected from the group consisting of SEQ ID NO: 16-18 that recognizes a human CH1 domain comprising at least one amino acid substitution selected from the group consisting of R133K, E137G, S138G, N192S, F193L, and S178Y, and (ii) a kappa light chain, and wherein the position of the substitution is based on EU numbering.